Engineered immune cells take aim at Hard-to-Treat myeloma
NCT ID NCT07760454
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This trial is testing an experimental therapy called CT0596, which uses a patient's own immune cells that are engineered to recognize and attack multiple myeloma cells. The study includes adults with relapsed or refractory multiple myeloma who have already tried at least three prior treatments. The goal is to see if this CAR-T cell therapy is safe, tolerable, and effective, and to understand how the cells behave in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CT0596 CAR-T cells (a type of engineered immune cell therapy)
- What this could lead to
- If successful, this could lead to a new treatment option that may achieve durable remission in patients with hard-to-treat multiple myeloma.
- What could go wrong
- This is an early-phase trial, so the treatment may not work for everyone and could cause severe side effects like cytokine release syndrome or neurological toxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Renji Hospital,Shanghai Jiao Tong University School Of Medicine
Shanghai, China
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells outsmart Treatment-Resistant myeloma?
- Can a lower dose of a myeloma drug keep the disease in check with fewer side effects?
- A pre-treatment pill may supercharge cancer-fighting immune cells
- New antibody combo aims to stall multiple Myeloma's return
- Real-World data may reveal best Second-Line therapy for multiple myeloma
- New universal cell therapy shows promise for Hard-to-Treat blood cancer